Introduction
Cancer is a major life-threatening disease worldwide. Approximately 14.1 million patients were newly diagnosed with cancer and 8.2 million people died from cancer in 2012 worldwide [1] . The global burden of cancer is expected to grow rapidly due to aging population [2] .
In Korea, cancer accounts for one in four deaths and more than 200,000 new cancer cases were diagnosed in 2013 [3] .
The number of cancer incidences and deaths are expected to increase with an aging population and westernized lifestyles [4] . Additionally, the economic burden of cancer in Korea increased approximately 1.8-fold, from $11,424 to $20,858 million, between 2000 and 2010 [5] .
In this context, cancer statistics are the most important indicator to assess the national cancer burden and form cancer prevention and control strategies. This article aims to provide nationwide cancer statistics including incidence, survival, prevalence, and mortality in 2014.
Data sources
The Korea Central Cancer Registry (KCCR) was established by the Ministry of Health and Welfare in 1980 as a nationwide hospital-based cancer registry. Since 1999, the KCCR has collected cancer incidence data nationwide by integrating a hospital-based KCCR database with data from regional cancer registry programs. The KCCR currently provides the nationwide cancer incidence, survival, and prevalence statistics annually [6] .
The KCCR built the Korea National Cancer Incidence Database (KNCI DB) from hospitals, 11 population-based registries, and additional medical chart reviews. The KNCI DB contains information regarding age, sex, region, date of diagnosis, primary cancer site, histological type, most valid diagnostic method, and SEER stage. The completeness of cancer incidence data for 2014 was estimated to be 97.8% based on the method proposed by Ajiki et al. [7] . The midyear population and cancer mortality data from 1983 to 2014 were obtained from Statistics Korea [8] . To ascertain vital status and to calculate survival and prevalence, the KNCI DB was linked to mortality data and population registration data from Ministry of the Interior.
Classification
All incidence cases were registered according to the International Classification of Diseases for Oncology, 3rd edition [9] and converted to the International Classification of Diseases, 10th edition (ICD-10) [10] . The mortality cases were registered according to ICD-10. All cancer cases were reported based on the 24 cancer types.
Statistical analyses
Rates were expressed as crude and age-standardized rates (CR and ASR, respectively) per 100,000 individuals. The crude rate was calculated as the total number of incidence/ mortality cases divided by the mid-year population of the specified years. The ASR is a weighted average of the agespecific rates, where the weights are the proportions of persons in the corresponding age groups of a standard population [11] . In this report, ASRs were calculated using Segi's world standard population [12] . The cumulative risk of developing cancer from birth to life expectancy was calculated using cumulative rates; that is, the sum of the age-specific rates from birth to life expectancy, as follows [13] . Trends in incidence/mortality rates were summarized as an annual percentage change (APC) by using a Joinpoint regression. APC is the average percentage change of rates and is calculated as follows [11] :
, where log(Ry)=b0+b1y, log(Ry) is the natural log transformed age standardized rates.
y=year, b0=intercept, b1=slope
The survival duration for each cancer case was determined as the interval between the date of initial diagnosis and the date of death, date of loss of follow-up, or closing date for follow-up. The 5-year relative survival rates were calculated as the ratios of the observed survival of the cancer patients to the expected survival of the general population, which was derived from the standard life table provided by Statistics Korea. Trends in 5-year relative survival rates were evaluated as percentage differences in 5-year relative survival rates from 1993-1995 and 2010-2014. Relative survival rates were calculated using the Ederer II method [14] with some minor corrections, based on an algorithm by Paul Dickman [15] .
Prevalent cases were defined as the number of cancer patients alive on January 1, 2015 among all cancer patients diagnosed between 1999 and 2014. Limited-duration prevalences were calculated using SEER*Stat software. Any p-values less than 0.05 were considered statistically significant. SEER*Stat 8.2.1 (National Cancer Institute, Bethesda, MD), Joinpoint 4. 1. 1 (National Cancer Institute), and SAS 9.3 (SAS Institute, Cary, NC) were used in this report.
higher in men (38.7%) than in women (33.1%) (data not shown).
The total CR and ASR for overall cancer incidences in 2014 were 427.6 and 270.7 per 100,000, respectively (Table 2) . According to sex, CRs for all sites combined were 444.9 per 100,000 in men and 410.3 per 100,000 in women. The ASRs were 302.2 and 255.5 per 100,000 in men and women, respectively. Stomach cancer (CR, 79.2 per 100,000) was the most common cancer in men, followed by lung (CR, 66.0 per 100,000), colorectal (CR, 63.8 per 100,000), liver (CR, 47.5 per 100,000), and prostate cancer (CR, 38.6 per 100,000). These five cancers accounted for 66.3% of newly diagnosed cases in men during the study period. In contrast, thyroid cancer (CR, 97.0 per 100,000) was the most common cancer among women, followed by breast (CR, 72.1 per 100,000), colorectal (CR, 42.5 per 100,000), stomach (CR, 38.5 per 100,000), and lung cancer (CR, 28.7 per 100,000). These five cancers accounted for 67.9% of cases in women.
Mortality
In 2014, the total number of deaths from cancer was 76,611, accounting for 28.6% of all deaths (Table 3) . Expressed based on sex, 62.5% and 37.5% of cancer deaths occurred in men and women, respectively ( Table 1) .
The total CR and ASR for cancer deaths were 150.9 and 85.1 per 100,000, respectively, in 2014 ( Limited-duration prevalent cases on January 1, 2015. These are patients who were diagnosed between January 1, 1999 and December 31, 2014 and who were alive on January 1, 2015. Multiple primary cancer cases were counted multiple times,
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According to the cancer sites, lung cancer (CR, 50.4 per 100,000) was the leading cause of death in men, followed by liver (CR, 34.0 per 100,000), stomach (CR, 22.7 per 100,000), colorectal (CR, 18.8 per 100,000), and pancreatic cancer (CR, 10.8 per 100,000). The top five causes of deaths from cancer in women included lung (CR, 18.3 per 100,000), colorectal (CR, 14.1 per 100,000), stomach (CR, 12.4 per 100,000), liver (CR, 11.6 per 100,000), and pancreatic cancer (CR, 9.3 per 100,000).
Trends in cancer incidence and mortality
Fig. 1 shows trends in cancer incidence and mortality from 1983 to 2014. The ASR for all-cancer incidence increased by 3.4% annually from 1999 to 2012, and then began to decrease from 2012 to 2014 (APC, -6.6%) ( CNS, central nervous system. a) Age-adjusted using the world standard population, b) Includes the gallbladder and other/ unspecified parts of the biliary tract. Includes the gallbladder and other/unspecified parts of the biliary tract. Includes the gallbladder and other/unspecified parts of the biliary tract. ill-defined around 2011 (Table 5 , Fig. 2 ). Especially, ASR for thyroid cancer has increased rapidly 22.4% from 1999 to 2011, but then decreased swiftly 10.8% annually starting in 2011. Incidence of breast cancer has increased constantly throughout the period, but APC was slowed from 2005. Conversely, the incidence rates of cervix and liver showed constant decrease for the whole period. The incidence rate for liver cancer has started to decrease since 1999. After 2011, decreasing rate for liver cancer was more steepen. The ASR for all-cancer mortality rate has been increased until 2002 (Table 6 , Fig. 1 nervous system, cervix uteri, and thyroid started to decrease in the early 2000s. However, cancers in stomach, larynx, testis, bladder, and non-Hodgkin lymphoma decreased starting in 1999 (Table 6, Fig. 3) . Cancers in the pancreas, breast, and prostate showed constant increasing trends for the whole period.
Age-specific incidence rates
Leukemia was the most commonly diagnosed cancer among children between 0 and 14 years of age. Thyroid cancer was the most common cancer among adolescents and young adults between 15 and 34 years of age (Table 7 ). For men, the incidence rate of cancer increased until age 70 (Fig. 4A) CNS, central nervous system. Other and ill-defined the most common among men 65 and over. In contrast, thyroid cancer was most commonly diagnosed among women 35 to 64 years old, while colorectal cancer was the most common among women 65 and older. Thyroid and breast cancer showed an inverted U-shaped incidence rates by age (Fig. 4B) .
Survival rates
The 5-year relative survival rates for all cancer combined improved remarkably in both sexes, from 41.2% in 1993-1995 to 70.3% in 2010-2014 (Table 8 , Fig. 5A ). After excluding thyroid cancer, the 5-year relative survival rates for all cancer still increased from 1993 to 2014 (Fig. 5B) .
The 5-year relative survival rate during 2010-2014 for all cancer combined was 62.2% in men and 78.2% in women, respectively. The 5-year relative survival rate for thyroid cancer was over 100%, while the 5-year relative survival rates for testis, prostate, and breast cancer were over 90% in 2010-2014 for both sexes, respectively. However, the 5-year relative survival rate for pancreatic cancer was only 10.1% in both sexes in 2010-2014.
When compared to the 5-year relative survival rate for men in 1993-1995, prostate cancer diagnosed from 2010 to 2014 showed the most outstanding improvement, followed by stomach cancer, leukemia, lip/oral cavity/pharynx and liver cancer. Among women, stomach cancer diagnosed during 2010-2014 showed the greatest improvement in 5-year rela- Crude prevalence rate: number of prevalent cases divided by the corresponding person-years of observation. Prevalent cases were defined as patients who were diagnosed between January 1, 1999 and December 31, 2014 and who were alive on January 1, 2015. Multiple primary cancer cases were counted multiple times, b)
Age-adjusted using the Segi's world standard population, c)
Includes the gallbladder and other/unspecified parts of the biliary tract. Table 9 . Crude and age-standardized rates of cancer prevalence by sex on January 1, 2015 in Korea VOLUME 49 NUMBER 2 APRIL 2017 303 tive survival rates compared to those between 1993 and1995, followed by leukemia, non-Hodgkin lymphoma, colorectal, and liver cancer.
